Quality-of-life and performance status results from the phase III RAINBOWstudy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

S. E. Al-Batran, E. Van Cutsem, S. C. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. N. Lipatov, T. Y. Kim, D. Cunningham, P. Rougier, K. Muro, A. M. Liepa, K. Chandrawansa, M. Emig, A. Ohtsu, H. Wilke

Research output: Contribution to journalArticlepeer-review

50 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Quality-of-life and performance status results from the phase III RAINBOWstudy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences